APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neuroendocrine Tumor Drug Industry Growth and Trends Forecast to 2032

19 December 2025114 pages

Choose your research edition.

Industry ResearchNeuroendocrine Tumor Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Tumor Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Tumor Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Tumor Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Neuroendocrine Tumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuroendocrine Tumor Drug include Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and Midatech Pharma Plc ., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neuroendocrine Tumor Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neuroendocrine Tumor Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neuroendocrine Tumor Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neuroendocrine Tumor Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Neuroendocrine Tumor Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neuroendocrine Tumor Drug Market by Company

Exelixis, Inc.

Foresee Pharmaceuticals, LLC

Hutchison MediPharma Limited

Intezyne, Inc

INVENT Pharmaceuticals, Inc.

Ipsen S.A.

Karyopharm Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Midatech Pharma Plc .

Millennium Pharmaceuticals, Inc.

MolMed S.p.A.

Northwest Biotherapeutics, Inc.

OctreoPharm Sciences GmbH

OXiGENE, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Novartis AG

Eisai

Neuroendocrine Tumor Drug Segment by Type

mTOR Protein Inhibitors

Tyrosine Kinase 3 Inhibitors

Growth Hormone Releasing Factor Antagonists

Somatostatin Receptor Agonists

Somatostatin Receptor Antagonists

Others

Neuroendocrine Tumor Drug Segment by Application

Hospital

Clinic

Others

Neuroendocrine Tumor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neuroendocrine Tumor Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Neuroendocrine Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of mTOR Protein Inhibitors Table 2. Major Company of Tyrosine Kinase 3 Inhibitors Table 3. Major Company of Growth Hormone Releasing Factor Antagonists Table 4. Major Company of Somatostatin Receptor Agonists Table 5. Major Company of Somatostatin Receptor Antagonists Table 6. Major Company of Others Table 7. Global Neuroendocrine Tumor Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 9. Global Neuroendocrine Tumor Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Neuroendocrine Tumor Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Neuroendocrine Tumor Drug Price by Type (2021-2026) & (US$/Unit) Table 13. Global Neuroendocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 14. Global Neuroendocrine Tumor Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Neuroendocrine Tumor Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Neuroendocrine Tumor Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Neuroendocrine Tumor Drug Price by Type (2027-2032) & (US$/Unit) Table 18. North America Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 19. North America Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 21. Europe Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 23. Asia-Pacific Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 25. Latin America Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 27. Middle East and Africa Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Neuroendocrine Tumor Drug Industry Trends Table 29. Neuroendocrine Tumor Drug Industry Drivers Table 30. Neuroendocrine Tumor Drug Industry Opportunities and Challenges Table 31. Neuroendocrine Tumor Drug Industry Restraints Table 32. Global Neuroendocrine Tumor Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Neuroendocrine Tumor Drug Revenue Market Share by Company (2021-2026) Table 34. Global Neuroendocrine Tumor Drug Sales by Company (2021-2026) & (W Units) Table 35. Global Neuroendocrine Tumor Drug Sales Share by Company (2021-2026) Table 36. Global Neuroendocrine Tumor Drug Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Neuroendocrine Tumor Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Neuroendocrine Tumor Drug Major Company Production Sites and Headquarters Table 39. Global Neuroendocrine Tumor Drug Company, Product Type & Application Table 40. Global Neuroendocrine Tumor Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Neuroendocrine Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Neuroendocrine Tumor Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Neuroendocrine Tumor Drug Sales by Region (2021-2026) & (W Units) Table 45. Global Neuroendocrine Tumor Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Neuroendocrine Tumor Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Neuroendocrine Tumor Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Neuroendocrine Tumor Drug Sales by Region (2027-2032) & (W Units) Table 50. Global Neuroendocrine Tumor Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Neuroendocrine Tumor Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Neuroendocrine Tumor Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Neuroendocrine Tumor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Neuroendocrine Tumor Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 56. Global Neuroendocrine Tumor Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Neuroendocrine Tumor Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Neuroendocrine Tumor Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Neuroendocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 61. Global Neuroendocrine Tumor Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Neuroendocrine Tumor Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Neuroendocrine Tumor Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Neuroendocrine Tumor Drug Price by Application (2027-2032) & (US$/Unit) Table 65. North America Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 66. North America Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 68. Europe Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 70. Asia-Pacific Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 72. Latin America Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 74. Middle East and Africa Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 75. Exelixis, Inc. Company Information Table 76. Exelixis, Inc. Business Overview Table 77. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 79. Exelixis, Inc. Recent Development Table 80. Foresee Pharmaceuticals, LLC Company Information Table 81. Foresee Pharmaceuticals, LLC Business Overview Table 82. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio Table 84. Foresee Pharmaceuticals, LLC Recent Development Table 85. Hutchison MediPharma Limited Company Information Table 86. Hutchison MediPharma Limited Business Overview Table 87. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio Table 89. Hutchison MediPharma Limited Recent Development Table 90. Intezyne, Inc Company Information Table 91. Intezyne, Inc Business Overview Table 92. Intezyne, Inc Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio Table 94. Intezyne, Inc Recent Development Table 95. INVENT Pharmaceuticals, Inc. Company Information Table 96. INVENT Pharmaceuticals, Inc. Business Overview Table 97. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 99. INVENT Pharmaceuticals, Inc. Recent Development Table 100. Ipsen S.A. Company Information Table 101. Ipsen S.A. Business Overview Table 102. Ipsen S.A. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio Table 104. Ipsen S.A. Recent Development Table 105. Karyopharm Therapeutics, Inc. Company Information Table 106. Karyopharm Therapeutics, Inc. Business Overview Table 107. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 109. Karyopharm Therapeutics, Inc. Recent Development Table 110. Lexicon Pharmaceuticals, Inc. Company Information Table 111. Lexicon Pharmaceuticals, Inc. Business Overview Table 112. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 114. Lexicon Pharmaceuticals, Inc. Recent Development Table 115. Midatech Pharma Plc . Company Information Table 116. Midatech Pharma Plc . Business Overview Table 117. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio Table 119. Midatech Pharma Plc . Recent Development Table 120. Millennium Pharmaceuticals, Inc. Company Information Table 121. Millennium Pharmaceuticals, Inc. Business Overview Table 122. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 124. Millennium Pharmaceuticals, Inc. Recent Development Table 125. MolMed S.p.A. Company Information Table 126. MolMed S.p.A. Business Overview Table 127. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio Table 129. MolMed S.p.A. Recent Development Table 130. Northwest Biotherapeutics, Inc. Company Information Table 131. Northwest Biotherapeutics, Inc. Business Overview Table 132. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 134. Northwest Biotherapeutics, Inc. Recent Development Table 135. OctreoPharm Sciences GmbH Company Information Table 136. OctreoPharm Sciences GmbH Business Overview Table 137. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio Table 139. OctreoPharm Sciences GmbH Recent Development Table 140. OXiGENE, Inc. Company Information Table 141. OXiGENE, Inc. Business Overview Table 142. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 144. OXiGENE, Inc. Recent Development Table 145. Jiangsu Hengrui Medicine Co., Ltd. Company Information Table 146. Jiangsu Hengrui Medicine Co., Ltd. Business Overview Table 147. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio Table 149. Jiangsu Hengrui Medicine Co., Ltd. Recent Development Table 150. Novartis AG Company Information Table 151. Novartis AG Business Overview Table 152. Novartis AG Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Novartis AG Neuroendocrine Tumor Drug Product Portfolio Table 154. Novartis AG Recent Development Table 155. Eisai Company Information Table 156. Eisai Business Overview Table 157. Eisai Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Eisai Neuroendocrine Tumor Drug Product Portfolio Table 159. Eisai Recent Development Table 160. North America Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 161. North America Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 162. North America Neuroendocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 163. North America Neuroendocrine Tumor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 164. North America Neuroendocrine Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 165. North America Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 166. North America Neuroendocrine Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 167. North America Neuroendocrine Tumor Drug Market Share by Country (2021-2026) Table 168. North America Neuroendocrine Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 169. North America Neuroendocrine Tumor Drug Market Share Forecast by Country (2027-2032) Table 170. Europe Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 171. Europe Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 172. Europe Neuroendocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 173. Europe Neuroendocrine Tumor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 174. Europe Neuroendocrine Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 175. Europe Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 176. Europe Neuroendocrine Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 177. Europe Neuroendocrine Tumor Drug Market Share by Country (2021-2026) Table 178. Europe Neuroendocrine Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 179. Europe Neuroendocrine Tumor Drug Market Share Forecast by Country (2027-2032) Table 180. Asia-Pacific Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 181. Asia-Pacific Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 182. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 183. Asia-Pacific Neuroendocrine Tumor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 184. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 185. Asia-Pacific Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 186. Asia-Pacific Neuroendocrine Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 187. Asia-Pacific Neuroendocrine Tumor Drug Market Share by Country (2021-2026) Table 188. Asia-Pacific Neuroendocrine Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 189. Asia-Pacific Neuroendocrine Tumor Drug Market Share Forecast by Country (2027-2032) Table 190. Latin America Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 191. Latin America Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 192. Latin America Neuroendocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 193. Latin America Neuroendocrine Tumor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 194. Latin America Neuroendocrine Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 195. Latin America Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 196. Latin America Neuroendocrine Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 197. Latin America Neuroendocrine Tumor Drug Market Share by Country (2021-2026) Table 198. Latin America Neuroendocrine Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 199. Latin America Neuroendocrine Tumor Drug Market Share Forecast by Country (2027-2032) Table 200. Middle East and Africa Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 201. Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 202. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Country (2021-2026) Table 203. Middle East and Africa Neuroendocrine Tumor Drug Sales Forecast by Country (2027-2032) & (W Units) Table 204. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 205. Middle East and Africa Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 206. Middle East and Africa Neuroendocrine Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 207. Middle East and Africa Neuroendocrine Tumor Drug Market Share by Country (2021-2026) Table 208. Middle East and Africa Neuroendocrine Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 209. Middle East and Africa Neuroendocrine Tumor Drug Market Share Forecast by Country (2027-2032) Table 210. Key Raw Materials Table 211. Raw Materials Key Suppliers Table 212. Neuroendocrine Tumor Drug Distributors List Table 213. Neuroendocrine Tumor Drug Customers List Table 214. Research Programs/Design for This Report Table 215. Authors List of This Report Table 216. Secondary Sources Table 217. Primary Sources List of Figures Figure 1. Neuroendocrine Tumor Drug Image Figure 2. Global Neuroendocrine Tumor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuroendocrine Tumor Drug Sales (2021-2032) & (W Units) Figure 5. mTOR Protein Inhibitors Image Figure 6. Global mTOR Protein Inhibitors Sales YoY Growth (2021-2032) & (W Units) Figure 7. Tyrosine Kinase 3 Inhibitors Image Figure 8. Global Tyrosine Kinase 3 Inhibitors Sales YoY Growth (2021-2032) & (W Units) Figure 9. Growth Hormone Releasing Factor Antagonists Image Figure 10. Global Growth Hormone Releasing Factor Antagonists Sales YoY Growth (2021-2032) & (W Units) Figure 11. Somatostatin Receptor Agonists Image Figure 12. Global Somatostatin Receptor Agonists Sales YoY Growth (2021-2032) & (W Units) Figure 13. Somatostatin Receptor Antagonists Image Figure 14. Global Somatostatin Receptor Antagonists Sales YoY Growth (2021-2032) & (W Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 17. Global Neuroendocrine Tumor Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Neuroendocrine Tumor Drug Market Share by Type 2025 VS 2032 Figure 19. North America Neuroendocrine Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Neuroendocrine Tumor Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Neuroendocrine Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Neuroendocrine Tumor Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Neuroendocrine Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Neuroendocrine Tumor Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Neuroendocrine Tumor Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 37. Global Neuroendocrine Tumor Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Neuroendocrine Tumor Drug Market Share by Application 2025 VS 2032 Figure 39. North America Neuroendocrine Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Neuroendocrine Tumor Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Neuroendocrine Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Neuroendocrine Tumor Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Neuroendocrine Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Neuroendocrine Tumor Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Neuroendocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. North America Neuroendocrine Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Neuroendocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Neuroendocrine Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Neuroendocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Europe Neuroendocrine Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Neuroendocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Neuroendocrine Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Neuroendocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Asia-Pacific Neuroendocrine Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Neuroendocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Neuroendocrine Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Neuroendocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Latin America Neuroendocrine Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Neuroendocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Neuroendocrine Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Neuroendocrine Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 66. Middle East and Africa Neuroendocrine Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Neuroendocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Neuroendocrine Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Neuroendocrine Tumor Drug Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Neuroendocrine Tumor Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • mTOR Protein Inhibitors
  • Tyrosine Kinase 3 Inhibitors
  • Growth Hormone Releasing Factor Antagonists
  • Somatostatin Receptor Agonists
  • Somatostatin Receptor Antagonists
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Exelixis, Inc.
  • Foresee Pharmaceuticals, LLC
  • Hutchison MediPharma Limited
  • Intezyne, Inc
  • INVENT Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Karyopharm Therapeutics, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Midatech Pharma Plc .
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Northwest Biotherapeutics, Inc.
  • OctreoPharm Sciences GmbH
  • OXiGENE, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Novartis AG
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroendocrine Tumor Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Neuroendocrine Tumor Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Neuroendocrine Tumor Drug Market by Type
  6. 1.3.1 mTOR Protein Inhibitors
  7. 1.3.2 Tyrosine Kinase 3 Inhibitors
  8. 1.3.3 Growth Hormone Releasing Factor Antagonists
  9. 1.3.4 Somatostatin Receptor Agonists
  10. 1.3.5 Somatostatin Receptor Antagonists
  11. 1.3.6 Others
  12. 1.4 Global Neuroendocrine Tumor Drug Market Size by Type
  13. 1.4.1 Global Neuroendocrine Tumor Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Neuroendocrine Tumor Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Neuroendocrine Tumor Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Neuroendocrine Tumor Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Neuroendocrine Tumor Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Neuroendocrine Tumor Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Neuroendocrine Tumor Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Neuroendocrine Tumor Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Neuroendocrine Tumor Drug Industry Trends
  2. 2.2 Neuroendocrine Tumor Drug Industry Drivers
  3. 2.3 Neuroendocrine Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Tumor Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Neuroendocrine Tumor Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Neuroendocrine Tumor Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Neuroendocrine Tumor Drug Price (2021-2026)
  4. 3.4 Global Neuroendocrine Tumor Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neuroendocrine Tumor Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Neuroendocrine Tumor Drug Company, Product Type & Application
  7. 3.7 Global Neuroendocrine Tumor Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neuroendocrine Tumor Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neuroendocrine Tumor Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neuroendocrine Tumor Drug Tier 1, Tier 2, and Tier 3
4 Neuroendocrine Tumor Drug Regional Status and Outlook
  1. 4.1 Global Neuroendocrine Tumor Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Neuroendocrine Tumor Drug Historic Market Size by Region
  3. 4.2.1 Global Neuroendocrine Tumor Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Neuroendocrine Tumor Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Neuroendocrine Tumor Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Neuroendocrine Tumor Drug Forecasted Market Size by Region
  7. 4.3.1 Global Neuroendocrine Tumor Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Neuroendocrine Tumor Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Neuroendocrine Tumor Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Neuroendocrine Tumor Drug by Application
  1. 5.1 Neuroendocrine Tumor Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Neuroendocrine Tumor Drug Market Size by Application
  6. 5.2.1 Global Neuroendocrine Tumor Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Neuroendocrine Tumor Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Neuroendocrine Tumor Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Neuroendocrine Tumor Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Neuroendocrine Tumor Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Neuroendocrine Tumor Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Neuroendocrine Tumor Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Neuroendocrine Tumor Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Exelixis, Inc.
  2. 6.1.1 Exelixis, Inc. Company Information
  3. 6.1.2 Exelixis, Inc. Business Overview
  4. 6.1.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio
  6. 6.1.5 Exelixis, Inc. Recent Developments
  7. 6.2 Foresee Pharmaceuticals, LLC
  8. 6.2.1 Foresee Pharmaceuticals, LLC Company Information
  9. 6.2.2 Foresee Pharmaceuticals, LLC Business Overview
  10. 6.2.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio
  12. 6.2.5 Foresee Pharmaceuticals, LLC Recent Developments
  13. 6.3 Hutchison MediPharma Limited
  14. 6.3.1 Hutchison MediPharma Limited Company Information
  15. 6.3.2 Hutchison MediPharma Limited Business Overview
  16. 6.3.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio
  18. 6.3.5 Hutchison MediPharma Limited Recent Developments
  19. 6.4 Intezyne, Inc
  20. 6.4.1 Intezyne, Inc Company Information
  21. 6.4.2 Intezyne, Inc Business Overview
  22. 6.4.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio
  24. 6.4.5 Intezyne, Inc Recent Developments
  25. 6.5 INVENT Pharmaceuticals, Inc.
  26. 6.5.1 INVENT Pharmaceuticals, Inc. Company Information
  27. 6.5.2 INVENT Pharmaceuticals, Inc. Business Overview
  28. 6.5.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  30. 6.5.5 INVENT Pharmaceuticals, Inc. Recent Developments
  31. 6.6 Ipsen S.A.
  32. 6.6.1 Ipsen S.A. Company Information
  33. 6.6.2 Ipsen S.A. Business Overview
  34. 6.6.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio
  36. 6.6.5 Ipsen S.A. Recent Developments
  37. 6.7 Karyopharm Therapeutics, Inc.
  38. 6.7.1 Karyopharm Therapeutics, Inc. Company Information
  39. 6.7.2 Karyopharm Therapeutics, Inc. Business Overview
  40. 6.7.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
  42. 6.7.5 Karyopharm Therapeutics, Inc. Recent Developments
  43. 6.8 Lexicon Pharmaceuticals, Inc.
  44. 6.8.1 Lexicon Pharmaceuticals, Inc. Company Information
  45. 6.8.2 Lexicon Pharmaceuticals, Inc. Business Overview
  46. 6.8.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  48. 6.8.5 Lexicon Pharmaceuticals, Inc. Recent Developments
  49. 6.9 Midatech Pharma Plc .
  50. 6.9.1 Midatech Pharma Plc . Company Information
  51. 6.9.2 Midatech Pharma Plc . Business Overview
  52. 6.9.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio
  54. 6.9.5 Midatech Pharma Plc . Recent Developments
  55. 6.10 Millennium Pharmaceuticals, Inc.
  56. 6.10.1 Millennium Pharmaceuticals, Inc. Company Information
  57. 6.10.2 Millennium Pharmaceuticals, Inc. Business Overview
  58. 6.10.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  60. 6.10.5 Millennium Pharmaceuticals, Inc. Recent Developments
  61. 6.11 MolMed S.p.A.
  62. 6.11.1 MolMed S.p.A. Company Information
  63. 6.11.2 MolMed S.p.A. Business Overview
  64. 6.11.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio
  66. 6.11.5 MolMed S.p.A. Recent Developments
  67. 6.12 Northwest Biotherapeutics, Inc.
  68. 6.12.1 Northwest Biotherapeutics, Inc. Company Information
  69. 6.12.2 Northwest Biotherapeutics, Inc. Business Overview
  70. 6.12.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
  72. 6.12.5 Northwest Biotherapeutics, Inc. Recent Developments
  73. 6.13 OctreoPharm Sciences GmbH
  74. 6.13.1 OctreoPharm Sciences GmbH Company Information
  75. 6.13.2 OctreoPharm Sciences GmbH Business Overview
  76. 6.13.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio
  78. 6.13.5 OctreoPharm Sciences GmbH Recent Developments
  79. 6.14 OXiGENE, Inc.
  80. 6.14.1 OXiGENE, Inc. Company Information
  81. 6.14.2 OXiGENE, Inc. Business Overview
  82. 6.14.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio
  84. 6.14.5 OXiGENE, Inc. Recent Developments
  85. 6.15 Jiangsu Hengrui Medicine Co., Ltd.
  86. 6.15.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
  87. 6.15.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
  88. 6.15.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio
  90. 6.15.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
  91. 6.16 Novartis AG
  92. 6.16.1 Novartis AG Company Information
  93. 6.16.2 Novartis AG Business Overview
  94. 6.16.3 Novartis AG Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Novartis AG Neuroendocrine Tumor Drug Product Portfolio
  96. 6.16.5 Novartis AG Recent Developments
  97. 6.17 Eisai
  98. 6.17.1 Eisai Company Information
  99. 6.17.2 Eisai Business Overview
  100. 6.17.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Eisai Neuroendocrine Tumor Drug Product Portfolio
  102. 6.17.5 Eisai Recent Developments
7 North America by Country
  1. 7.1 North America Neuroendocrine Tumor Drug Sales by Country
  2. 7.1.1 North America Neuroendocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Neuroendocrine Tumor Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Neuroendocrine Tumor Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Neuroendocrine Tumor Drug Market Size by Country
  6. 7.2.1 North America Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Neuroendocrine Tumor Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Neuroendocrine Tumor Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Neuroendocrine Tumor Drug Sales by Country
  2. 8.1.1 Europe Neuroendocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Neuroendocrine Tumor Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Neuroendocrine Tumor Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Neuroendocrine Tumor Drug Market Size by Country
  6. 8.2.1 Europe Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Neuroendocrine Tumor Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Neuroendocrine Tumor Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Neuroendocrine Tumor Drug Sales by Country
  2. 9.1.1 Asia-Pacific Neuroendocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Neuroendocrine Tumor Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Neuroendocrine Tumor Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Neuroendocrine Tumor Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Neuroendocrine Tumor Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Neuroendocrine Tumor Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Neuroendocrine Tumor Drug Sales by Country
  2. 10.1.1 South America Neuroendocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Neuroendocrine Tumor Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Neuroendocrine Tumor Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Neuroendocrine Tumor Drug Market Size by Country
  6. 10.2.1 South America Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Neuroendocrine Tumor Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Neuroendocrine Tumor Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country
  2. 11.1.1 Middle East and Africa Neuroendocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Neuroendocrine Tumor Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Neuroendocrine Tumor Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Neuroendocrine Tumor Drug Value Chain Analysis
  2. 12.1.1 Neuroendocrine Tumor Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Neuroendocrine Tumor Drug Production Mode & Process
  7. 12.2 Neuroendocrine Tumor Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Neuroendocrine Tumor Drug Distributors
  10. 12.2.3 Neuroendocrine Tumor Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst